^
    Back
    Association details:
    Biomarker:CD52 expression
    Cancer:Prolymphocytic Leukemia
    Drug:Campath (alemtuzumab) (CD52 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/05/2023
    Excerpt:
    T-Cell Prolymphocytic Leukemia….Retreatment with alemtuzumab (IV) ± pentostatin (if CD52 expression is still positive and relapse after a period of remission following first-line therapy).
    Secondary therapy:
    pentostatin